Policy & Regulation
Syndax to discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting
5 December 2023 -

Syndax Pharmaceuticals (Nasdaq: SNDX), a US-based clinical stage biopharmaceutical company that is developing an innovative pipeline of cancer therapies, announced on Monday that it will host an in-person investor event, along with a live webcast, on Monday, 11 December 2023, at 7:00 am PT / 10:00 am ET during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.

The event will include new data for both the axatilimab and revumenib programs, and members of the Syndax management team will be joined by the following key opinion leaders:

Daniel Wolff, MD, professor of Hematology, Department of Internal Medicine III of the University of Regensburg.

Eytan M. Stein, MD, chief, program for Drug Development in Leukemia, Department of Medicine, Memorial Sloan Kettering Cancer Center.

Ghayas C. Issa, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

Joshua F. Zeidner, MD, associate professor of Medicine, chief, Leukemia Research, University of North Carolina, Lineberger Comprehensive Cancer Center.

Neerav N. Shukla, MD, chief, Pediatric Translational Medicine Service, Memorial Sloan Kettering Cancer Center.